Hallin and colleagues demonstrate the preclinical activity of the KRASG12C-specific inhibitor MRTX849 in a series of in vitro and in vivo studies with supporting pilot clinical efficacy. Variable responsiveness despite effective KRASG12C inhibition highlights both the promise and potential need for combinatorial strategies to optimally target KRASG12C-driven cancers.See related article by Hallin et al., p. 54.

中文翻译：

---

帮助可以匹配炒作吗？KRASG12C 特异性抑制剂及其他。

Hallin 及其同事在一系列支持试点临床疗效的体外和体内研究中证明了 KRASG12C 特异性抑制剂 MRTX849 的临床前活性。尽管 KRASG12C 抑制有效，但反应性可变，这突出了组合策略以最佳方式靶向 KRASG12C 驱动的癌症的前景和潜在需求。参见 Hallin 等人的相关文章，p。54.